CUPERTINO, Calif., Aug. 5, 2020 /PRNewswire/ -- DURECT
Corporation (Nasdaq: DRRX) announced today that James E. Brown, President and CEO, Michael H. Arenberg, Chief Financial Officer and
Dr. WeiQi Lin, Executive Vice
President of R&D will be participating in a fireside chat at
the BTIG Biotechnology Conference 2020, Monday, August 10, 2020 at 11:00 a.m. EDT / 8:00 a.m.
PDT. Institutional investors that are participating in
the conference may request a virtual one-on-one meeting through the
conference coordinators.
A live audio webcast of the presentation will be available by
accessing
http://wsw.com/webcast/btig/drrx/
The live audio webcast of the presentation will also be
available by accessing DURECT's homepage at www.durect.com and
clicking on the "Investors" tab. If you are unable to
participate during the live webcast, the call will be archived on
DURECT's website in the "Event Calendar" of the "Investors"
section.
About DURECT Corporation
DURECT is a biopharmaceutical company committed to transforming
the treatment of acute organ injury and chronic liver diseases by
advancing novel and potentially lifesaving therapies based on its
endogenous epigenetic regulator program. DURECT's lead candidate,
DUR-928 is an endogenous sulfated oxysterol and an epigenetic
regulator. It represents a new class of therapeutics with a unique
mechanism of action. DUR-928 epigenetically modulates the
expression of multiple clusters of master genes that are involved
in many important cell signaling pathways, through which it
stabilizes mitochondria, reduces lipotoxicity, regulates
inflammatory or stress responses, and promotes cell survival.
This drug candidate is currently in Phase 2 development for the
treatment of alcoholic hepatitis (AH) and the treatment of COVID-19
patients with acute liver or kidney injury as well as Phase 1
development for the treatment of nonalcoholic steatohepatitis
(NASH). DURECT's proprietary drug delivery technologies are
designed to enable new indications and enhanced attributes for
small-molecule and biologic drugs. One late-stage product candidate
in this category is POSIMIR® (bupivacaine
extended-release solution), an investigational locally-acting,
non-opioid analgesic intended to provide up to three days of
continuous pain relief after surgery. For more information about
DURECT, please visit www.durect.com.
DURECT Forward-Looking Statement
The statements in
this press release regarding the potential for DUR-928 to treat
patients with AH, NASH, COVID-19, or other acute organ injury and
chronic liver diseases , plans for clinical development of DUR-928
and the potential benefits and uses of our drug candidates,
including the potential use of DUR-928 to treat AH, NASH and
COVID-19 patients with acute liver or kidney injury and other acute
and chronic diseases, and the potential of POSIMIR to treat
post-surgical pain are forward-looking statements involving risks
and uncertainties that can cause actual results to differ
materially from those in such forward-looking statements. Potential
risks and uncertainties include, but are not limited to, the risks
that future clinical trials of DUR-928 do not confirm the results
of trials conducted on small numbers of patients, are not started
when anticipated, take longer to conduct than anticipated, do not
generate similar positive results as generated in earlier clinical
or pre-clinical trials, or do not demonstrate the safety or
efficacy of DUR-928 in a statistically significant manner, the risk
of disruptions to our business operations resulting from the
COVID-19 pandemic, the risk that additional time and resources may
be required for development, testing and regulatory approval of
DUR-928, potential adverse effects arising from the testing or use
of our drug candidates, the potential that the FDA will not approve
POSIMIR, our potential failure to maintain our collaborative
agreements with third parties or consummate new collaborations and
risks related to our ability to obtain capital to fund operations
and expenses. Further information regarding these and other risks
is included in DURECT's Form 10-Q filed on August 4, 2020 under the heading "Risk
Factors."
NOTE: POSIMIR® and SABER® are trademarks
of DURECT Corporation. Other referenced trademarks belong to
their respective owners. DUR-928 and POSIMIR are
investigational drug candidates under development and have not been
approved for commercialization by the U.S. Food and Drug
Administration or other health authorities for any indication.
View original
content:http://www.prnewswire.com/news-releases/durect-to-present-at-the-btig-biotechnology-conference-2020-301106416.html
SOURCE DURECT Corporation